ERBB2 and breast carcinoma: When comparing data from 2016 vs 2010 (Figure 3), NACT use in patients with HER2+ breast cancer (OR 4.17 [95% CI 3.70–4.60]), and TNBC (OR 3.81 [95% CI 3.38–4.31]) increased significantly over time.